Europe – Treatments and vaccines for COVID-19

The European Medicines Agency's (EMA) is interacting with developers of potential COVID-19 treatments and vaccines to enable promising medicines to reach patients as soon as possible. It is also making use of real-world data to monitor the safety and effectiveness of medicines used in patients with COVID-19.

Update: On 3 July 2020, the European Commission granted a conditional marketing authorisation for remdesivir, for the treatment of COVID-19 in adults and adolescents from 12 years of age with pneumonia who require supplemental oxygen.

This follows the recommendation of the CHMP from 25 June 2020 and allows the medicine to be marketed in the EU.

The invented name for the medicine is Veklury…